Colorectal peritoneal metastases: Optimal management review |
| |
Authors: | Juan Manuel S nchez-Hidalgo Lidia Rodr guez-Ortiz lvaro Arjona-S nchez Sebasti n Rufi n-Pe a ngela Casado-Adam Antonio Cosano- lvarez Javier Brice o-Delgado |
| |
Institution: | Juan Manuel Sánchez-Hidalgo, Lidia Rodríguez-Ortiz, Álvaro Arjona-Sánchez, Sebastián Rufián-Peña, Ángela Casado-Adam, Antonio Cosano-Álvarez, Javier Briceño-Delgado, Department of General and Digestive Surgery, Reina Sofia University Hospital, Cordoba 14004, Spain |
| |
Abstract: | The peritoneum is a common site of dissemination for colorrectal cancer, with a poorer prognosis than other sites of metastases. In the last two decades, it has been considered as a locoregional disease progression and treated as such with curative intention treatments. Cytoreductive surgery(CRS) and hyperthermic intraperitoneal chemotherapy(HIPEC) is the actual reference treatment for these patients as better survival results have been reached as compared to systemic chemotherapy alone, but its therapeutic efficacy is still under debate. Actual guidelines recommend that the management of colorectal cancer with peritoneal metastases should be led by a multidisciplinary team carried out in experienced centers and consider CRS + HIPEC for selected patients. Accumulative evidence in the last three years suggests that this is a curative treatment that may improve patients disease-free survival, decrease the risk of recurrence, and does not increase the risk of treatment-related mortality. In this review we aim to gather the latest results from referral centers and opinions from experts about the effectiveness and feasibility of CRS + HIPEC for treating peritoneal disease from colorectal malignancies. |
| |
Keywords: | Peritoneal metastases Colorectal cancer Cytoreductive surgery Hyperthermic intraperitoneal chemotherapy Peritoneal carcinomatosis |
本文献已被 CNKI 等数据库收录! |
| 点击此处可从《世界胃肠病学杂志(英文版)》浏览原始摘要信息 |
|